Department of Biotechnology, Faculty of Science, Lincoln University College, Selangor, Malaysia
Copyright ©2020, Korea Centers for Disease Control and Prevention
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
SARS-CoV | MERS-SARS | SARS-CoV-2 | |
---|---|---|---|
Coronaviriniae Genera | b-coronavirus, lineage B | b-coronavirus, lineage C | b-coronavirus, lineage B |
Virus type | RNA virus | RNA virus | RNA virus |
Total length of DNA sequence | 29,751 | 30,111 | 29,903 |
Discovery (y) | 2003 | 2012 | 2019 |
Origin | Guangdong province, China | Arabian Peninsula | Hubei province, China |
Total No. of cases worldwide (WHO report) | > 8,000 | 2,494 | 2,230,439 (Till 17th April 2020) |
Total No. of affected countries (WHO report) | 26 | 27 | 210 |
Total number of death cases (WHO report) | 916 | 858 | 150,837 (As of 17th April 2020) |
Mortality | >10% | 34.4% | 2.10% |
Transmission mode | -Droplets (coughing and sneezing) -Close contact with an infected person |
-Droplets (coughing and sneezing) -Close contact with an infected person |
-Droplets (coughing and sneezing) -Close contact with an infected person or even asymptomatic ones |
Transmission medium | Animal to human Human to human |
Animal to human Human to human |
Animal to human Human to human |
Transmission region | Globally | Regionally | Globally |
Cellular receptor | Angiotensin-Converting Enzyme 2 (ACE 2) | Dipeptidyl peptidase 4 (DDP4) | Angiotensin-Converting Enzyme 2 (ACE2) |
Reservoir | Palm Civets and Bats | Bats and Camels | Bats |
Receptor binding domain (RBD) | C-domain | C-domain | C-domain |
IFN-γ inhibitor | Yes | Yes | Unknown |
Viral replication efficiency | High | Higher | Higher |
Pathogenicity | Higher | High | High |
Clinical symptoms (WHO report) | Fever, malaise, myalgia, headache, diarrhea, and shivering (rigors) | Fever, cough, and shortness of breath | Fever, tiredness, and dry cough |
Prevention | -Hand wash -Wear mask and gloves -Physical distancing |
-Hand wash -Wear mask and glove -Physical distancing |
-Hand wash -Wear mask and gloves -Physical distancing |
Treatment | Glucocorticoid and interferon | No vaccine or specific treatment | No specific antiviral treatment |
Drugs | Mechanism |
---|---|
Remdesivir | Blocks viral RNA-dependent RNA polymerase activity (inhibits RNA replication from the RNA template) |
Chloroquine and hydroxychloroquine | Inhibits endocytosis by increasing the acidity in endosomes and prevents the entry of virus into the host cell. |
Lopinavir and ritonavir | Inhibits RNA translation process |
Lopinavir and ritonavir plus interferon-beta | Inhibits viral replication |
Camostat mesylate | Inhibits enzymatic activity of type II transmembrane serine protease (TMPRSS2) which is important for infectious viral entry into the host cell |
Darunavir | Blocks viral replication |
BCR-ABL kinase inhibitor imatinib | Inhibits fusion of virions with the endosomal membrane |
Arbidol | Inhibits membrane fusion of the viral envelope |
Ribavarin | Inhibits viral RNA synthesis and mRNA capping |
Ribavirin plus interferon-beta | Shuts down viral replication |
Umifenovir | Inhibits fusion of virions with the endosomal membrane |
Oseltamivir | Inhibits RNA translation process |
Interferon-beta | Triggers the activation of innate antiviral immunity |
Favipiravir | Blocks viral RNA-dependent RNA polymerase activity (inhibits RNA replication from RNA template) |
Monoclonal antibodies | Inhibits viral infection via binding to the virus |
MERS-CoV = Middle East respiratory syndrome coronavirus; SARS-CoV = severe acute respiratory syndrome coronavirus; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; WHO = World Health Organization.
SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.